Refractoriness to recombinant human epoetin (rhuepo) treatment

Handbook of Dialysis Therapy

Volumn , Issue , 2008, Pages 812-831

  Stivelman, John C ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Northwest Kidney Centers   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79961090346     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4197-9.50067-3     Document Type: Chapter

References (16)

1. Barany P, Divino Filho JC, Bergstrom J High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997, 29(4):565-568.
2. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002, 346:469-475.
3. Eschbach JW, Varma A, Stivelman JC Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia?. Nephrol Dial Transplant 2002, 17(suppl 5):2-7.
4. Fishbane S, Berns JS Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005, 68:1337-1343.
5. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996, 7:2654-2657.
6. Kalantar-Zadeh K, Ikizler TA, Block G, et al. Malnutrition-inflammation complex syndrome in dialysis patients: Causes and consequences. Am J Kidney Dis 2003, 42:864-881.
7. Lacson E, Ofsthun N, Lazarus JM Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003, 41:111-124.
8. National Kidney Foundation NKF-K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006, 47(suppl 3):S1-146.
9. This report demonstrates the close linkage among inflammation, hypoalbuminemia, and rHuEPO resistance.
10. An important exposition of the phenomenon of pure red-cell aplasia with rHuEPO treatment.
11. This article provides an accounting of causes of resistance to treatment over one year in a large regional dialysis provider, indicating that the vast majority of resistance is reversible.
12. This contribution provides a thoughtful and compelling exposition of the impact of intercurrent illness, hospitalization, and regulatory expectations on the stability of response to rHuEPO treatment.
13. This article is an important exposition of the value and reliability of TSAT and ferritin values in assessing the presence of true iron deficiency.
14. An overall review of the malnutrition-inflammation complex syndrome and its sequelae.
15. This article outlines the high likelihood of major hemoglobin fluctuation in large populations occurring during the average patient-year interval, and the striking potential variability within a single patient's values.
16. This monograph offers the third series of evidence-based guidelines for treatment of the anemia of chronic renal failure, including appropriate hemoglobin goals, guidelines for rHuEPO and intravenous iron therapy, mechanisms for optimizing hemoglobin, and sources of resistance to therapy.